XTX Topco Ltd Buys 100,679 Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

XTX Topco Ltd raised its stake in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) by 142.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 171,463 shares of the company’s stock after acquiring an additional 100,679 shares during the quarter. XTX Topco Ltd’s holdings in Unicycive Therapeutics were worth $136,000 at the end of the most recent reporting period.

Separately, Geode Capital Management LLC boosted its position in Unicycive Therapeutics by 30.3% during the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company’s stock valued at $417,000 after acquiring an additional 122,089 shares in the last quarter. Hedge funds and other institutional investors own 40.42% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $7.50 target price on shares of Unicycive Therapeutics in a research report on Friday, April 11th. Guggenheim initiated coverage on Unicycive Therapeutics in a research report on Monday, April 21st. They set a “buy” rating and a $6.00 target price on the stock.

Unicycive Therapeutics Price Performance

Unicycive Therapeutics stock opened at $0.64 on Wednesday. The stock has a market capitalization of $77.09 million, a price-to-earnings ratio of -0.66 and a beta of 2.15. Unicycive Therapeutics, Inc. has a 1-year low of $0.20 and a 1-year high of $1.25. The business has a fifty day moving average price of $0.58 and a 200-day moving average price of $0.60.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). On average, equities research analysts anticipate that Unicycive Therapeutics, Inc. will post -0.23 earnings per share for the current fiscal year.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.